Key points and suggestions for the update of 2024 “ Diagnosis and Management Guidelines for Chronic Coronary Syndrome Patients in China”

The “ Diagnosis and Management Guidelines for Chronic Coronary Syndrome Patients in China ” published in 2024 was led by the Atherosclerosis and Coronary Heart Disease Group of the Cardiology Branch of the Chinese Medical Association and the Editorial Board of the Chinese Journal of Cardiovascular Diseases, in conjunction with the Intervention Group, Intravascular Imaging and Functional Group, Cardiovascular Disease Imaging Group, and Basic Science Group. The guideline is the first in China to provide guidance for the diagnosis and management of patients with chronic coronary syndrome (CCS), comprehensively introducing the definition, diagnostic process, treatment strategies, and long-term management of CCS. The guideline aims to improve the prognosis and quality of life by providing the best diagnostic or treatment methods. This article focuses on the antithrombotic therapy, lipid-lowering therapy, and management of special populations for patients with CCS, further interpreting the updates and recommendations in the guidelines.